AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0850
+0.0450 (+1.11%)
As of 10:18AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.0400
Open4.1300
Bid4.10 x 900
Ask4.11 x 3200
Day's Range4.0400 - 4.1700
52 Week Range3.5400 - 33.6300
Volume693,310
Avg. Volume4,153,671
Market Cap512.635M
Beta (3Y Monthly)2.93
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target Est8.00
Trade prices are not sourced from all markets
  • Moody's5 days ago

    Akorn, Inc. -- Moody's downgrades Akorn's ratings to Caa1; outlook revised to negative

    Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.

  • Business Wire9 days ago

    Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharmaceutical company. According to the complaint, on April 24, 2017, Fresenius SE Co. KGaA ("Fresenius") agreed to acquire Akorn in a deal valued at $4.3 billion.

  • After court case loss, drug maker Akorn's CEO will step down
    American City Business Journals9 days ago

    After court case loss, drug maker Akorn's CEO will step down

    After losing a court case in Delaware last week, the CEO of drug company Akorn Inc. will step down. Last week the Supreme Court of the State of Delaware upheld a lower court’s decision to allow Fresenius Kabi AG to terminate its April 2017 $4.3 billion merger deal with Lake Forest, Illinois-based Akorn. After the court loss was announced, Akorn said CEO Raj Rai will retire.

  • Is Akorn, Inc. (AKRX) A Good Stock To Buy?
    Insider Monkey10 days ago

    Is Akorn, Inc. (AKRX) A Good Stock To Buy?

    Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Reuters11 days ago

    Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

    Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. Akorn said that its Chief Executive Officer Raj Rai will retire but will remain in his post till a successor is named.

  • Bloomberg12 days ago

    Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Deal

    Officials of Akorn said on Friday that Chief Executive Raj Rai was retiring now that its dispute with the German pharma company had been ended by the appellate court’s decision. A panel of judges upheld a finding that a drop in revenue and other problems prior to the deal’s closing triggered Fresenius’s right to abandon the buyout. Shares of Akorn plunged Friday as much as 37 percent, to their lowest intraday price in more than eight years.

  • GlobeNewswire12 days ago

    Supreme Court of the State of Delaware Rules Against Akorn, New CEO Search Underway

    Akorn, Inc. (AKRX) today said it will move forward and rebuild shareholder value as an independent company following the disappointing decision from the Supreme Court of the State of Delaware upholding the lower court’s decision to allow Fresenius Kabi AG to terminate the April 2017 merger agreement. With the litigation process concluded, Akorn’s Board of Directors announced that it is engaged in a formal search for a new chief executive officer to lead the company into its next phase. Current CEO Raj Rai has decided to retire and will assist the board to ensure a smooth transition and remain in his role until the hiring date of the new chief executive.

  • Fresenius Wins Ruling on Canceled Buyout; Akorn Shares Fall
    Bloomberg12 days ago

    Fresenius Wins Ruling on Canceled Buyout; Akorn Shares Fall

    Shares of Akorn plunged, dropping as much as 37 percent to their lowest intraday price in more than eight years. The case’s “record adequately supports the Court of Chancery’s determination that Akorn suffered a material adverse effect” that excused Fresenius from closing the deal, the state’s highest court said Friday.

  • Financial Times12 days ago

    [$$] Akorn tumbles after US court upholds ruling on Fresenius deal cancellation

    Shares in US generic drugmaker Akorn dropped 21 per cent on Friday after a US court upheld its decision to allow Germany’s Fresenius to walk away from a $4.8bn takeover of the company. The ruling by the chief justice of the Delaware Supreme Court, the jurisdiction where most US corporate disputes are fought, ends an acrimonious dispute between the two companies that emerged after Fresenius agreed to pay a 40 per cent premium to acquire Illinois-based Akorn in April 2017. Before closing the deal, Akorn’s revenues fell sharply and a whistleblower contacted Fresenius about shortcoming in the target’s compliance with drug development standards.

  • Here's Why Akorn Pharmaceuticals Is Sinking Today
    Motley Fool13 days ago

    Here's Why Akorn Pharmaceuticals Is Sinking Today

    It looks as if the company's former suitor will get a chance to run from the altar.

  • GlobeNewswire23 days ago

    Akorn Receives Product Approval

    LAKE FOREST, Ill., Nov. 26, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a new Abbreviated New Drug.

  • Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?
    Zacks29 days ago

    Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?

    Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.

  • Is Akorn (AKRX) Stock a Suitable Pick for Value Investors?
    Zackslast month

    Is Akorn (AKRX) Stock a Suitable Pick for Value Investors?

    Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • See what the IHS Markit Score report has to say about Akorn Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Akorn Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswirelast month

    Investor Alert - Akorn, Inc. (AKRX) – Kehoe Law Firm, P.C. Investigating Potential Claims Against Certain Officers and Directors of Akorn, Inc.

    Shares of Akorn (AKRX) fell over 48% last month, according to data provided by S&P Global Market Intelligence. The news wasn't that surprising: On the first day of October, a judge ruled that German healthcare giant Fresenius could walk away from its bid to acquire the smaller drug company for $4.75 billion. Further, Motley Fool reported that “.

  • Associated Presslast month

    Akorn: 3Q Earnings Snapshot

    The Lake Forest, Illinois-based company said it had a loss of 56 cents per share. Losses, adjusted for asset impairment costs and amortization costs, were 6 cents per share. The results did not meet Wall ...

  • GlobeNewswirelast month

    Akorn Provides Third Quarter 2018 Results

    LAKE FOREST, Ill., Nov. 06, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the third quarter.

  • Here's Why Akorn, Inc. Fell 48.6% in October
    Motley Foollast month

    Here's Why Akorn, Inc. Fell 48.6% in October

    A judge gave Fresenius the green light to walk away from the now-infamous merger.

  • GlobeNewswire2 months ago

    Akorn Receives Product Approval

    LAKE FOREST, Ill., Oct. 29, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that, on October 26, 2018, it received a new.

  • PR Newswire2 months ago

    Resideo Technologies Set to Join S&P MidCap 400; Akorn to Join S&P SmallCap 600

    NEW YORK , Oct. 23, 2018 /PRNewswire/ -- Resideo Technologies Inc. (NYSE: REZI) will replace Akorn Inc. (NASD: AKRX) in the S&P MidCap 400, and Akorn will replace Big 5 Sporting Goods Corp. (NASD: BGFV) ...

  • ACCESSWIRE2 months ago

    Akorn to Press Buyout Lawsuit Further, Extensive Product Line, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Akorn, Inc. (AKRX), a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is involved in a lawsuit with Fresenius SE for canceling a $4.3 billion buyout of AKRX. AKRX specializes in generic pharmaceutical products in alternative dosage forms.

  • GlobeNewswire2 months ago

    Akorn Appeals Fresenius Kabi Ruling

    LAKE FOREST, Ill., Oct. 18, 2018 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that the company filed a notice of appeal to.